Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 03 April, 2020

Morgan Stanley&CoLLC

Rule 38.5 - ABBVIE INC.

RNS Number : 7377I
Morgan Stanley & Co. LLC
03 April 2020
 

 

  FORM 38.5

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER  RULES, 2007 (AS AMENDED)

 

DEALINGS BY CONNECTED EXEMPT MARKET-MAKERS

 

1.  KEY INFORMATION

 Name of exempt market-maker

  Morgan Stanley & Co. LLC

 Company dealt in

  ABBVIE INC.

 Class of relevant security to which the dealings being disclosed relate (Note 1)

  US$0.01 COMMON STOCK

 Date of dealing

  02 APRIL 2020

 

 

2.  DEALINGS  (Note 2)

 

(a)  Purchases and sales

 Total number of relevant secuities accquired

 Highest price paid (Note 3)

 Lowest price paid (Note 3)

   1,603,232

 75.5000 USD

 71.4500 USD

 

 Total number of relevant secuities disposed

 Highest price paid (Note 3)

 Lowest price paid (Note 3)

   1,919,117

 75.5000 USD

 71.4500 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

 Product name, e.g. CFD

 Nature of transaction

  (Note 4)

 Number of relevant securities

  (Note 5)

 Price per unit

 N/A

 N/A

 N/A

 N/A

 

 

(c)  Options transactions in respect of existing relevant securities

 

i)  Writing, selling, purchasing or varying

 

 Product name, eg call option

 Writing, selling, purchasing, varying etc

 Number of securities to which the option relates (Note 5)

 Exercise Price

 Type, e.g American, European etc

 Expiry Date

 Option money paid/received per unit (Note 3)

 PUT

 PURCHASE

 100

 65.0000

A

 03/04/2020

 0.2200 USD

 CALL

 PURCHASE

 100

 80.0000

A

 03/04/2020

 0.0200 USD

 CALL

 PURCHASE

 100

 78.0000

A

 03/04/2020

 0.0900 USD

 CALL

 PURCHASE

 100

 78.0000

A

 03/04/2020

 0.1100 USD

 CALL

 PURCHASE

 300

 75.0000

A

 03/04/2020

 0.6300 USD

 CALL

 PURCHASE

 100

 80.0000

A

 17/04/2020

 0.6600 USD

 CALL

 PURCHASE

 100

 74.0000

A

 03/04/2020

 0.6600 USD

 CALL

 PURCHASE

 1,400

 100.0000

A

 18/09/2020

 0.7000 USD

 CALL

 PURCHASE

 100

 79.0000

A

 17/04/2020

 0.8500 USD

 CALL

 PURCHASE

 200

 80.0000

A

 15/05/2020

 2.0700 USD

 CALL

 PURCHASE

 100

 75.0000

A

 17/04/2020

 2.2300 USD

 CALL

 PURCHASE

 100

 87.5000

A

 21/08/2020

 2.2700 USD

 CALL

 PURCHASE

 100

 87.5000

A

 21/08/2020

 2.2700 USD

 CALL

 PURCHASE

 100

 80.0000

A

 19/06/2020

 3.2700 USD

 CALL

 PURCHASE

 200

 75.0000

A

 15/05/2020

 4.2600 USD

 PUT

 PURCHASE

 100

 80.0000

A

 03/04/2020

 5.3900 USD

 CALL

 PURCHASE

 4,000

 70.0000

A

 15/01/2021

 9.9700 USD

 CALL

 SALE

 100

 77.0000

A

 09/04/2020

 0.8700 USD

 CALL

 SALE

 600

 105.0000

A

 15/01/2021

 0.8800 USD

 PUT

 SALE

 100

 65.0000

A

 15/05/2020

 2.5300 USD

 PUT

 SALE

 100

 50.0000

A

 15/01/2021

 3.2700 USD

 PUT

 SALE

 200

 80.0000

A

 20/11/2020

 14.6800 USD

 

(ii) Exercising

 

 Product name, eg call option

 Number of securities

 Exercise price per unit (Note 3)

 PUT

 200

 92.5000  USD

 

 

3. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full Details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 Date of disclosure

 03 APRIL 2020

 Contact Name

Craig Horsley

 Telephone Number

+44(141) 245 7736

 Name of offeree/offeror with which connected

ABBVIE INC.

Nature of connection (Note 6)

Advisory

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISESSUSADESSELL

a d v e r t i s e m e n t